

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following subgroups of patients with advanced triple-negative breast cancer (TNBC) derived progression-free survival (PFS) benefit with the addition of pembrolizumab to chemotherapy in the Phase III KEYNOTE-355 trial?
 - a. All patients with previously untreated disease regardless of PD-L1 expression
 - b. Patients with previously untreated disease with PD-L1 expression (CPS of ≥ 10)
2. Based on the results from the Phase III OlympiAD study, for a patient with mTNBC with BRCA germline mutation, what is the optimal way to administer olaparib?
 - a. As monotherapy in the first line
 - b. As maintenance after first-line platinum-based chemotherapy
3. Results from the placebo-controlled Phase III BROCADE 3 trial demonstrated PFS benefit with which of the following PARP inhibitors in combination with carboplatin/paclitaxel for patients with HER2-negative mBC with germline BRCA mutation?
 - a. Olaparib
 - b. Talazoparib
 - c. Veliparib
 - d. Niraparib
4. Which of the following best describes the mechanism of action of sacituzumab govitecan in patients with recurrent mTNBC?
 - a. Anti-PD-1 monoclonal antibody
 - b. Anti-PD-L1 monoclonal antibody
 - c. Nectin-4-directed antibody-drug conjugate (ADC)
 - d. Trop-2-directed ADC